ConductScience.org, home

Paper ยท 21984977

Functional viability profiles of breast cancer.

Brough R and 21 others. Cancer Discov, 2011. Cited by 123 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Functional viability profiles of breast cancer. Papers, record 21984977. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21984977

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Functional viability profiles of breast cancer.
PubMed
Journal
Cancer Discov
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
123
iCite
Relative citation ratio, by iCite
2.35
iCite
Revised in PubMed
2025-05-29
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brough RRachel
2Frankum JRJessica R
3Sims DDavid
4Mackay AAlan
5Mendes-Pereira AMAna M
6Bajrami IIlirjana
7Costa-Cabral SSara
8Rafiq RRumana
9Ahmad ASAmar S
10Cerone MAMaria Antonietta

1 to 10 of 22Source PubMed

See all 22 authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Cell Line, Tumor
Female
Gene Expression Profiling
Genetic Testing
Humans
M Phase Cell Cycle Checkpoints
Mutation
PTEN Phosphohydrolase
Protein Kinases
Receptors, Estrogen

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
11566Cancer Research UKUnited KingdomPubMedPubMed
A8363Cancer Research UKUnited KingdomPubMedPubMed
BREAST CANCER NOW RESEARCH CENTREBreast Cancer NowUnited KingdomPubMedPubMed
P30 CA082103NCI NIH HHSUnited StatesP30CA082103PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in22,586,571Functional subtyping of breast cancer.https://conductscience.org/library/papers/22586571

Source PubMed

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110,838,414A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.J Biomol Screen1999https://conductscience.org/library/papers/10838414PubMed
218,388,863A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.EMBO J2008https://conductscience.org/library/papers/18388863PubMed
319,903,845Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.Cancer Res2009https://conductscience.org/library/papers/19903845PubMed
420,029,424A census of amplified and overexpressed human cancer genes.Nat Rev Cancer2010https://conductscience.org/library/papers/20029424PubMed
518,239,126Cancer proliferation gene discovery through functional genomics.Science2008https://conductscience.org/library/papers/18239126PubMed
619,536,107Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.Nat Rev Cancer2009https://conductscience.org/library/papers/19536107PubMed
72,218,183More powerful procedures for multiple significance testing.Stat Med1990https://conductscience.org/library/papers/2218183PubMed
811,553,815Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A2001https://conductscience.org/library/papers/11553815PubMed
920,049,735Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.EMBO Mol Med2009https://conductscience.org/library/papers/20049735PubMed
1020,453,85853BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.Nat Struct Mol Biol2010https://conductscience.org/library/papers/20453858PubMed

Cited by84

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.

PMIDTitleJournalYearIn PapersSource
42,068,645Genetically predicted TTK inhibition and its association with reduced breast cancer risk: a two-step Mendelian randomization study of potential gut microbiome mediation.Clinics (Sao Paulo)2026https://conductscience.org/library/papers/42068645PubMed
40,565,246The ADCK Kinase Family: Key Regulators of Bioenergetics and Mitochondrial Function and Their Implications in Human Cancers.Int J Mol Sci2025https://conductscience.org/library/papers/40565246PubMed
37,533,462Synthetic lethal approaches to target cancers with loss of PTEN function.Genes Dis2023https://conductscience.org/library/papers/37533462PubMed
37,443,114BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.Mol Cancer2023https://conductscience.org/library/papers/37443114PubMed
37,346,953New cyclic glycolipids from Silene succulenta promote in vitro MCF-7 breast carcinoma cell apoptosis by cell cycle arrest and in silico mitotic Mps1/TTK inhibition.RSC Adv2023https://conductscience.org/library/papers/37346953PubMed
37,190,140The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo.Cancers (Basel)2023https://conductscience.org/library/papers/37190140PubMed
36,934,096Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.Nat Commun2023https://conductscience.org/library/papers/36934096PubMed
36,439,873Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC.Int J Biol Sci2022https://conductscience.org/library/papers/36439873PubMed
36,405,310Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors.Front Chem2022https://conductscience.org/library/papers/36405310PubMed
36,085,291Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas.Oncogenesis2022https://conductscience.org/library/papers/36085291PubMed

1 to 10 of 84

See all 84 cited by

Genes41

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21984977

GET https://conductscience.org/api/papers/v1/21984977/authors?page=2